# Jade Biosciences, Inc.: financial statements, quarterly

JBIO · Nasdaq · CIK 1798749 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/jbio.md) · [Financials](/companies/jbio/financials.md) · [Filings](/companies/jbio/filings.md) · [Insiders](/companies/jbio/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/jbio/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [16.9](/filings/0001798749-24-000059.md) | [17.8 d](/filings/0001558370-25-003750.md) | [20.1](/filings/0001558370-25-005564.md) | [21.2](/filings/0001798749-24-000049.md) | [13.6](/filings/0001193125-25-281525.md) | [1.5 d](/filings/0001558370-25-003750.md) | [20.0](/filings/0001193125-26-212088.md) | [22.5](/filings/0001193125-26-341242.md) | [22.0](/filings/0001193125-25-281525.md) | [28.5 d](/filings/0001193125-26-096550.md) | [36.1](/filings/0001193125-26-212088.md) | [50.1](/filings/0001193125-26-341242.md) |
| Operating income | $m | [(21.4)](/filings/0001798749-24-000059.md) | [(22.1) d](/filings/0001558370-25-003750.md) | [(24.6)](/filings/0001558370-25-005564.md) | [(26.2)](/filings/0001798749-24-000049.md) | [(15.0)](/filings/0001193125-25-281525.md) | [(6.4) d](/filings/0001558370-25-003750.md) | [(23.4)](/filings/0001193125-26-212088.md) | [(27.8)](/filings/0001193125-26-341242.md) | [(27.4)](/filings/0001193125-25-281525.md) | [(35.0) d](/filings/0001193125-26-096550.md) | [(43.4)](/filings/0001193125-26-212088.md) | [(58.9)](/filings/0001193125-26-341242.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-25-281525.md) | not reported | not reported | [0.0](/filings/0001193125-26-341242.md) | [0.0](/filings/0001193125-25-281525.md) | [0.1 d](/filings/0001193125-26-096550.md) | [0.0](/filings/0001193125-26-212088.md) | [0.0](/filings/0001193125-26-341242.md) |
| Net income | $m | [(19.6)](/filings/0001798749-24-000059.md) | [(20.4) d](/filings/0001558370-25-003750.md) | [(23.2)](/filings/0001558370-25-005564.md) | [(24.8)](/filings/0001798749-24-000059.md) | [(16.3)](/filings/0001193125-25-281525.md) | [(5.4) d](/filings/0001558370-25-003750.md) | [(38.2)](/filings/0001193125-26-341242.md) | [(32.1)](/filings/0001193125-26-341242.md) | [(25.2)](/filings/0001193125-25-281525.md) | [(31.9) d](/filings/0001193125-26-096550.md) | [(40.4)](/filings/0001193125-26-341242.md) | [(55.8)](/filings/0001193125-26-341242.md) |
| Diluted EPS | $ per share | [(0.71)](/filings/0001798749-24-000059.md) | not reported | [(0.83)](/filings/0001558370-25-005564.md) | [(0.86)](/filings/0001798749-24-000049.md) | [(5.16)](/filings/0001193125-25-281525.md) | not reported | [(12.10)](/filings/0001193125-26-212088.md) | [(0.86)](/filings/0001193125-26-341242.md) | [(0.48)](/filings/0001193125-25-281525.md) | not reported | [(0.57)](/filings/0001193125-26-212088.md) | [(0.76)](/filings/0001193125-26-341242.md) |
| Basic EPS | $ per share | [(0.71)](/filings/0001798749-24-000059.md) | not reported | [(0.83)](/filings/0001558370-25-005564.md) | [(0.86)](/filings/0001798749-24-000049.md) | [(5.16)](/filings/0001193125-25-281525.md) | not reported | [(12.10)](/filings/0001193125-26-212088.md) | [(0.86)](/filings/0001193125-26-341242.md) | [(0.48)](/filings/0001193125-25-281525.md) | not reported | [(0.57)](/filings/0001193125-26-212088.md) | [(0.76)](/filings/0001193125-26-341242.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | period not labelled (2024-06-17) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [23.5](/filings/0001558370-25-003750.md) | [9.1](/filings/0001558370-24-007985.md) | not reported | [31.1](/filings/0001798749-24-000049.md) | [31.1](/filings/0001798749-24-000059.md) | [69.4](/filings/0001193125-26-096550.md) | [44.2](/filings/0001558370-25-005564.md) | [221](/filings/0001193125-25-179853.md) | [50.1](/filings/0001193125-25-281525.md) | [88.4](/filings/0001193125-26-341242.md) | [55.1](/filings/0001193125-26-212088.md) | [107](/filings/0001193125-26-341242.md) |
| Current assets | $m | [124](/filings/0001558370-25-003750.md) | [103](/filings/0001558370-24-007985.md) | not reported | [111](/filings/0001798749-24-000049.md) | [90.6](/filings/0001798749-24-000059.md) | [69.7](/filings/0001193125-26-096550.md) | [77.4](/filings/0001558370-25-005564.md) | [223](/filings/0001193125-25-179853.md) | [201](/filings/0001193125-25-281525.md) | [349](/filings/0001193125-26-341242.md) | [319](/filings/0001193125-26-212088.md) | [471](/filings/0001193125-26-341242.md) |
| Total assets | $m | [127](/filings/0001558370-25-003750.md) | [107](/filings/0001558370-24-007985.md) | not reported | [112](/filings/0001798749-24-000049.md) | [91.0](/filings/0001798749-24-000059.md) | [72.8](/filings/0001193125-26-096550.md) | [77.5](/filings/0001558370-25-005564.md) | [224](/filings/0001193125-25-179853.md) | [202](/filings/0001193125-25-281525.md) | [350](/filings/0001193125-26-341242.md) | [319](/filings/0001193125-26-212088.md) | [472](/filings/0001193125-26-341242.md) |
| Current liabilities | $m | [17.6](/filings/0001558370-25-003750.md) | [15.5](/filings/0001558370-24-007985.md) | not reported | [17.0](/filings/0001798749-24-000049.md) | [10.3](/filings/0001798749-24-000059.md) | [12.0](/filings/0001193125-26-096550.md) | [2.4](/filings/0001558370-25-005564.md) | [21.6](/filings/0001193125-25-179853.md) | [22.4](/filings/0001193125-25-281525.md) | [16.5](/filings/0001193125-26-341242.md) | [22.3](/filings/0001193125-26-212088.md) | [31.6](/filings/0001193125-26-341242.md) |
| Total liabilities | $m | [18.0](/filings/0001558370-25-003750.md) | [15.9](/filings/0001558370-24-007985.md) | not reported | [17.3](/filings/0001798749-24-000049.md) | [10.5](/filings/0001798749-24-000059.md) | [120](/filings/0001193125-26-096550.md) | [2.5](/filings/0001558370-25-005564.md) | [22.4](/filings/0001193125-25-179853.md) | [23.1](/filings/0001193125-25-281525.md) | [17.3](/filings/0001193125-26-341242.md) | [23.0](/filings/0001193125-26-212088.md) | [32.2](/filings/0001193125-26-341242.md) |
| Shareholders' equity | $m | [109](/filings/0001558370-25-005564.md) | [90.9](/filings/0001558370-25-005564.md) | [0.0](/filings/0001193125-26-096550.md) | [(0.6)](/filings/0001193125-25-281525.md) | [(16.9)](/filings/0001193125-25-281525.md) | [(46.8)](/filings/0001193125-26-341242.md) | [(83.5)](/filings/0001193125-26-341242.md) | [202](/filings/0001193125-26-341242.md) | [179](/filings/0001193125-25-281525.md) | [333](/filings/0001193125-26-341242.md) | [296](/filings/0001193125-26-341242.md) | [440](/filings/0001193125-26-341242.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(15.6) d](/filings/0001798749-24-000059.md) | [(14.8) d](/filings/0001558370-25-003750.md) | [(23.7)](/filings/0001558370-25-005564.md) | [(20.4) d](/filings/0001798749-24-000049.md) | [(6.8)](/filings/0001193125-25-281525.md) | [(11.0) d](/filings/0001558370-25-003750.md) | [(18.8)](/filings/0001193125-26-212088.md) | [(20.2) d](/filings/0001193125-26-341242.md) | [(22.1) d](/filings/0001193125-25-281525.md) | [(33.6) d](/filings/0001193125-26-096550.md) | [(24.1)](/filings/0001193125-26-212088.md) | [(43.7) d](/filings/0001193125-26-341242.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001798749-24-000059.md) | [0.1 d](/filings/0001558370-25-003750.md) | not reported | not reported | not reported | not reported | not reported | not reported | [0.1 d](/filings/0001193125-25-281525.md) | [0.0 d](/filings/0001193125-26-096550.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [24.5](/filings/0001798749-23-000060.md) | [24.8](/filings/0001558370-24-007985.md) | [25.2](/filings/0001798749-24-000049.md) | [27.6](/filings/0001798749-24-000059.md) | [27.8](/filings/0001558370-25-005564.md) | [28.8](/filings/0001798749-24-000049.md) | [3.2](/filings/0001193125-25-281525.md) | [3.2](/filings/0001193125-26-212088.md) | [28.4](/filings/0001193125-26-341242.md) | [39.6](/filings/0001193125-25-281525.md) | [57.8](/filings/0001193125-26-212088.md) | [61.1](/filings/0001193125-26-341242.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 63,597,387 at 2026-08-03, from the cover of the [10-Q filed 2026-08-10](/filings/0001193125-26-341242.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.